Last updated on June 2020

COVID-19 Treatment Trial: Investigational Medication as a Non-antiviral Immunomodulator

Brief description of study

The study is designed to compare two COVID-19 treatment regimens in hospitalized adult subjects who are diagnosed with severe COVID 19.  The investigational medication is called CD24Fc.

Participants will be randomly assigned to one of two treatment "arms" for the study and neither the participant, nor the study team will know which arm each participant is assigned to.
- Arm A: CD24Fc / Best Available Treatment
- Arm B: placebo / Best Available Treatment 

CD24Fc will be administered as single dose of 480 mg via IV infusion on Day 1 of the study. Total of 230 subjects will be enrolled; half will receive CD24Fc and half will receive placebo. All subjects will be treated with the best available treatment. The follow up period is 28 days.

Clinical Study Identifier: NCT04317040

Find a site near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.